| __timestamp | Neurocrine Biosciences, Inc. | Pharming Group N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 17986000 | 4042025 |
| Thursday, January 1, 2015 | 32480000 | 5279557 |
| Friday, January 1, 2016 | 68081000 | 8073913 |
| Sunday, January 1, 2017 | 169906000 | 44864073 |
| Monday, January 1, 2018 | 248932000 | 53488904 |
| Tuesday, January 1, 2019 | 354100000 | 65896361 |
| Wednesday, January 1, 2020 | 433300000 | 69968267 |
| Friday, January 1, 2021 | 583300000 | 92047281 |
| Saturday, January 1, 2022 | 752700000 | 131819000 |
| Sunday, January 1, 2023 | 887600000 | 87501000 |
| Monday, January 1, 2024 | 1007200000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Neurocrine Biosciences, Inc. and Pharming Group N.V. have taken different paths in this regard over the past decade. From 2014 to 2023, Neurocrine Biosciences saw a staggering increase in SG&A expenses, growing by nearly 4,800%, from approximately $18 million to $888 million. In contrast, Pharming Group N.V. managed a more modest increase of around 2,100%, from $4 million to $88 million.
This data suggests that while Neurocrine Biosciences has expanded its operations significantly, it has also incurred higher costs. Pharming Group N.V., on the other hand, appears to have maintained a more controlled growth in expenses. Understanding these trends can provide valuable insights for investors and industry analysts looking to gauge the financial health and strategic direction of these companies.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or Pharming Group N.V.
Comparing SG&A Expenses: Amgen Inc. vs Pharming Group N.V. Trends and Insights
Who Optimizes SG&A Costs Better? argenx SE or Pharming Group N.V.
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Incyte Corporation vs Pharming Group N.V.
Breaking Down SG&A Expenses: Pharming Group N.V. vs ImmunityBio, Inc.
Who Optimizes SG&A Costs Better? Pharming Group N.V. or Supernus Pharmaceuticals, Inc.